Search

Author/Creator Shames, David

1. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. Issue 2 (21st February 2022)

Authors:
West, Howard Jack; McCleland, Mark; Cappuzzo, Federico; Reck, Martin; Mok, Tony SK; Jotte, Robert M; Nishio, Makoto; Kim, Eugene; Morris, Stefanie; Zou, Wei; Shames, David; Das Thakur, Meghna; Shankar, Geetha; Socinski, Mark A
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 2(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. (September 2017)

Authors:
Bubendorf, Lukas; Dafni, Urania; Schöbel, Martin; Finn, Stephen P.; Tischler, Verena; Sejda, Aleksandra; Marchetti, Antonio; Thunnissen, Erik; Verbeken, Eric K.; Warth, Arne; Sansano, Irene; Cheney, Richard; Speel, Ernst Jan M.; Nonaka, Daisuke; Monkhorst, Kim; Hager, Henrik; Martorell, Miguel; S...
Journal:
Lung cancer
Issue:
Volume 111(2017)
Page Start:
143
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search